Appel, Dominik; Hummel, Regina; Weidemeier, Martin et al.
Pharmacologic Inhibition of ADAM10 Attenuates Brain Tissue Loss, Axonal Injury and Pro-inflammatory Gene Expression Following Traumatic Brain Injury in MiceFRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY. Bd. 9. 2021
Chmitorz, A; Ottenhausen, M; Kalasauskas, D et al.
Pharmacological Neuroenhancement, Perceived Stress, and Resilience in Spine Surgeons-A Cross-Sectional SurveyWorld Neurosurg. Bd. S1878-8750. H. 21. 2021 S. 01672-7
Rösler, M; Retz, W; Turner, D
Pharmacotherapy of ADHD in Adults.Riederer P, Laux G, Nagatsu T, Le W, Riederer C (Hrsg). NeuroPsychopharmacotherapy. Springer Nature Switzerland 2021
Wolff, Jan; Reissner, Pamela; Hefner, Gudrun et al.
Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disordersPLOS ONE. Bd. 16. H. 7. 2021
Borgmann, Hendrik; Boehm, Katharina; Brandt, Maximilian Peter et al.
Phase 2 of the Coronavirus Pandemic in Urology: Ramping Up Surgical Caseload and Resident Training while COVID-19 Infections DecreaseUROLOGIA INTERNATIONALIS. Bd. 105. H. 7-8. 2021 S. 724-725
Hajda, Jacek; Leuchs, Barbara; Angelova, Assia L. et al.
Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal AdenocarcinomaCLINICAL CANCER RESEARCH. Bd. 27. H. 20. 2021 S. 5546-5556
Oh, Do-Youn; de Braud, Filippo; Bridgewater, John et al.
Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancerANNALS OF ONCOLOGY. Bd. 32. 2021 S. S333-S333
Lawitz, Eric J.; Reiberger, Thomas; Schattenberg, Joern M. et al.
PHASE IB STUDY OF THE SOLUBLE GUANYLATE CYCLASE ACTIVATOR BI 685509 IN PATIENTS WITH MILD AND MODERATE HEPATIC IMPAIRMENTHEPATOLOGY. Bd. 74. 2021 S. 1243A-1244A
Krajnak, Slavomir; Decker, Thomas; Schollenberger, Lukas et al.
Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2-breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Bd. 147. H. 11. 2021 S. 3391-3400
Marme, Frederik; Stickeler, Elmar; Furlanetto, Jenny et al.
Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021